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Abstract 
 
Introduction:  Meropenem  and  piperacillin tazobactam  have  similar  indications, 
spectrum of antimicrobial actions, and cost. When selecting between two antibiotics 
with similar efficacy, one may want the antibiotic with the least harm, such as C. 
difficile associated diarrhea (CDAD). 
 
Aim & Objectives: This study tested the hypothesis that patients on piperacillin 
tazobactam had a lower incidence of CDAD than patients on meropenem. 
 
Methods: A retrospective analysis was performed that included patients who received 
meropenem  or  piperacillin tazobactam  during  their  admissions  to  Ridge  Meadows 
Hospital, Canada from September 2007 to August 2009. This study had a subgroup 
analysis on patients with risk factors of developing CDAD: male, over 65 years old, 
staying longer than 28 days in healthcare settings, receiving concurrent risk factor 
medications, not on Saccharomyces boulardii in the previous two months, and not on 
oral metronidazole, intravenous metronidazole, or oral vancomycin in the previous 
two months. 
 
Results: There were 168 patients in the meropenem group and 122 patients in the 
piperacillin tazobactam  group.  No  significant  difference  was  found  between 
meropenem and piperacillin tazobactam with respect to incidence of CDAD (3.57% 
and  4.92%,  respectively;  p=0.5676),  two month  in hospital  mortality  (34.52% and 
36.89%, respectively; p=0.7102), and composite outcome of CDAD and two month 
in hospital  mortality  (37.50%  and  40.16%,  respectively;  p=0.7142).  All  subgroup 
analyses showed no difference in incidence of CDAD between the two antibiotics.  
 
Conclusions: There was no evidence to support patients on piperacillin tazobactam 
had a lower incidence of CDAD or mortality than patients on meropenem. Further 
research is still needed to help selecting the safest antibiotic for patients. 
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Introduction 
 
Clostridium difficile is the most clinically relevant bacteria known to cause antibiotic 
associated diarrhea and is responsible for 15 25% of cases of antibiotic associated 
diarrhea.
1 The incidence of C. difficile associated diarrhea (CDAD) in hospitalized 
patients is approximately 8% and accounts for 20 30% of cases of hospital acquired 
diarrhea.
2 
Meropenem  and  piperacillin tazobactam  are  time dependent  killing,  β lactamase 
resistant  antibiotics  that  are  active  against  gram negative  aerobes,  gram positive 
aerobes, and anaerobic bacteria.
3,4 Both meropenem and piperacillin tazobactam are 
indicated for treatment of lower respiratory tract, intra abdominal, gynecologic, and 
skin infections.
5,6 Both drugs have similar costs, and review of their respective drug 
monographs  suggests  that adverse effect  profiles  are  very similar.
5,6  Because both 
antibiotics have similar indications and adverse effect profiles, selecting one antibiotic 
over the other can be difficult. When selecting between two antibiotics with similar 
efficacy, one may want the antibiotic with the least harm, such as CDAD. Knowing 
the  prevalence  of  CDAD  with  meropenem  and  piperacillin tazobactam  may  help 
health institutions in reducing incidence of antibiotic associated diarrhea. 
It  has  been  demonstrated  that  piperacillin tazobactam  inhibits  growth  and  toxin 
production of C. difficile.
7 In two institutions, CDAD rates increased by 200% or 
more  during  a  shortage  of  piperacillin tazobactam.
8,9  However,  piperacillin 
tazobactam has also been associated with CDAD. In one institution, the incidence of 
CDAD decreased by 47% during the same piperacillin tazobactam shortage period.
10 
However, there is currently no information on the prevalence of CDAD in subjects 
exposed to meropenem. 
The present study was designed to test the hypothesis that patients on piperacillin 
tazobactam had a lower incidence of CDAD than patients on meropenem. This study 
also  compared  the  incidence  of  in hospital  mortality  within  two  months  of 
meropenem or piperacillin tazobactam use. 
 
Methods 
 
This study was a retrospective analysis of all patients who received meropenem or 
piperacillin tazobactam during their admissions to Ridge Meadows Hospital, Canada 
from September 2007 to August 2009. There was no protocol in place in choosing 
between the two antibiotics. The data was obtained using the health record software 
Meditech Version 3.26 (Westwood, Massachusetts, USA) and patients’ chart records 
in the hospital. CDAD was defined as having more than 2 documented unformed or 
watery stools in 24 hours plus a positive assay for toxin B in a stool sample.
2,11 The 
episode of CDAD was attributed to the use of meropenem or piperacillin tazobactam 
if the C. difficile toxin was found during, or within two months of, the antibiotic 
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The following patients were excluded from the study: patients under 18 years of age, 
patients who received both piperacillin tazobactam and meropenem in a two month 
period,  patients  who  developed  CDAD  in  the  two  months  prior  to  the  use  of 
meropenem  or  piperacillin tazobactam,  and  patients  with  gastrointestinal  tract 
colonization of pathogens also known to cause infectious diarrhea (Figure 1). 
The  primary  outcome  of  this  study  was  the  incidence  of  CDAD.  The  secondary 
outcomes were two month in hospital mortality, and composite outcome of CDAD or 
two month  mortality.  This  study  also  looked  at  a  subgroup  of  patients  with  risk 
factors for developing CDAD: male gender
12,13, above 65 years of age at the end of 
meropenem  or  piperacillin tazobactam  therapy
14,  prolonged  (>  28  days)  stay  in 
health care settings in the previous 6 years
15, use of risk factor medications that were 
given  within  two  months  of  meropenem  or  piperacillin tazobactam  (antineoplastic 
agents
16, tacrolimus
17, histamine 2 receptor antagonists
18, proton pump inhibitors
18, 
non steroidal anti inflammatory drugs
19, and systemic antibiotics except vancomycin 
and  metronidazole),  and  no  exposure  to  oral  Saccharomyces  boulardii,  oral 
vancomycin,  oral  metronidazole,  or  intravenous  metronidazole  within  two  months 
prior to meropenem or piperacillin tazobactam use. 
The incidence of CDAD with piperacillin tazobactam was predicted to be 7%. This 
was based on a study that compared incidence of CDAD in patients on piperacillin 
tazobactam  and  cefotaxime  (7%  vs.  53%).
20  There  is  no  published  data  on  the 
incidence of CDAD with meropenem. We estimated that the CDAD incidence rate of 
meropenem was between that of the piperacillin tazobactam and cefotaxime (7% vs. 
53%). Because meropenem is active against the clinical isolates of C. difficile
21, we 
did not foresee that its incidence of CDAD could be as high as 53%. The incidence of 
CDAD with meropenem was arbitrarily set at 22%, which was 15% higher than the 
estimated  piperacillin tazobactam  rate  (7%).  A  sample  size  calculation  with 
dichotomous outcome variables, a two tailed alpha of 5%, and a beta of 80% was 
used.
22 A minimum of 86 patients was needed per group to detect a difference of 15% 
between the two groups. 
The  two sided  Fisher’s  exact  test  was  used  to  compare  data  from  two  treatment 
groups. The criterion of statistical significance was set at p < 0.05. Statistical tests 
were  performed  using  the  computer  software  GraphPad  Prism  version  4.00  for 
Windows, (GraphPad Software, San Diego, California USA). 
 
Results 
 
Medical  records  were  reviewed  for  a  total  of  333  patients  (Figure  1).  Thirty five 
patients in the meropenem group and 32 patients in the piperacillin tazobactam group 
were  excluded.  There  were  a  total  of  168  meropenem treated  patients  and  122 
piperacillin tazobactam treated patients included in the analysis. The sample size was 
sufficient to detect an effect difference of about 12% between the two groups. The 
demographic  data  showed  that  the  piperacillin tazobactam  group  had  a  higher 
percentage  of  males  than  the  meropenem  group  (Figure  2;  61.48%  and  47.62%, 
respectively; p = 0.0235). International Journal of Collaborative Research on Internal Medicine & Public Health 
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Table  2  showed  no  significant  difference  between  meropenem  and  piperacillin 
tazobactam  groups  with  respect  to  incidence  of  CDAD  (3.57%  and  4.92%, 
respectively;  p  =  0.5676),  two month  in hospital  mortality  (34.52%  and  36.89%, 
respectively;  p  =  0.7102),  and  composite  outcome  of  CDAD  and  two month  in 
hospital mortality (37.50% and 40.16%, respectively). In each subgroup analysis in 
Table 3, the piperacillin tazobactam group had a slightly higher CDAD incidence than 
the meropenem group. However, the difference did not reach statistical significance. 
 
Discussion 
 
Overall,  the  present  study  showed  that  piperacillin tazobactam  did  not  have  a 
significantly lower incidence of CDAD than meropenem (Table 2). The results should 
not warrant the use of one antibiotic over the other to reduce the incidence of CDAD. 
The two month in hospital mortality rate was also not significantly different between 
the meropenem and piperacillin tazobactam groups (Table 2). The lack of significance 
was speculated to be due to a lack of statistical power. The composite outcome of 
incidence of CDAD or two month in hospital mortality was measured to improve the 
statistical power. The results should not warrant the use of one antibiotic over the 
other to reduce C. difficile related mortality. It is important to note that the severity of 
diseases could be different between the two antibiotic groups, and thereby offset the 
difference in mortality rates, though this possibility was not explored in this study. 
Factors that increased the risk of developing CDAD included the following: advanced 
age,  prolonged  duration  of  stay  in  healthcare  settings,  concurrent  risk  factor 
medications, and no previous exposure to oral S. boulardii, oral vancomycin, oral 
metronidazole,  or  intravenous  metronidazole.  The  demographic  data  showed  no 
significant difference in the above noted risk factors between the meropenem and 
piperacillin tazobactam groups (Table 1). It suggested that the lack of difference of 
CDAD rates between the two groups was unlikely due to the confounding variables. 
However,  the  meropenem  group  had  significantly  more  male  patients  than  the 
piperacillin tazobactam group. Two studies found that male patients were more prone 
to have CDAD than female patients, although the mechanism is still unclear.
12,13 In 
contrast, two studies showed female patients were more prone to have CDAD than 
male  patients.
23,24  It  is  inconclusive  therefore,  whether  gender  is  a  risk  factor  for 
CDAD. 
In any events, the subgroup analysis showed no significant difference in incidence of 
CDAD between the meropenem and piperacillin tazobactam groups in male patients 
(Table 3). The subgroup analysis also showed no significant difference in incidence of 
CDAD between the two antibiotics in patients at higher risk of developing CDAD. It 
suggested that selecting piperacillin tazobactam over meropenem did not reduce the 
incidence of CDAD in high risk patients.  
It is interesting to note that the incidence of CDAD in the piperacillin tazobactam 
group was lower than the rate reported in the study by Settle et al (4.92% and 7%, 
respectively).
20 Differences in settings, demographics, and study designs might have 
contributed to the difference in the incidence. It is important to note that the study by 
Settle et al. was conducted in geriatric wards. In the piperacillin tazobactam group in International Journal of Collaborative Research on Internal Medicine & Public Health 
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the current study, the incidence of CDAD in elderly patients was 6.67% (Table 3), 
which was comparable to the rate in the study by Settle et al. 
The  present  study  had  its  limitations.  The  first  limitation  was  that  there  was  a 
relatively small sample size (a total of 290 patients after exclusion), and thus lacked 
statistical power to detect small differences between the meropenem and piperacillin 
tazobactam groups. The absolute difference in incidence of CDAD between the two 
groups was 1.35% (Table 2), which was much smaller than the estimated difference 
used  in  the  sample  size  calculation  (15%).  It  appeared  that  the  current  study 
overestimated the difference between the incidence of CDAD with meropenem and 
piperacillin tazobactam. To detect an absolute difference of 1.35%, a sample size of 
3500 patients would be needed per group. This would require the patient data in the 
hospital in the last 40 years. The hospital lacks the available data. 
The second limitation was that the present study was performed at a single centre. We 
had no access to patient medical information prior to admission. Moreover, this study 
was retrospective, and thus could not eliminate all confounders. For example, it did 
not screen each patient for all possible pathogens for infectious diarrhea. Nasogastric 
tube  feeding
25,  peri partum  (4  weeks  before  to  4  weeks  after  delivery)
11,  serious 
underlying  illness comorbidities,  immune compromising  conditions,  and 
gastrointestinal  surgery  and  disorders  have  also  been  related  to  development  of 
CDAD.
26 Therefore, the incidence of CDAD in this study might not be exclusively 
related  to  meropenem  or  piperacillin tazobactam  usage  alone.  Despite  that,  the 
objective of this study was to investigate incidence of antibiotic associated diarrhea 
but not diarrhea caused by antibiotics. Increase in incidence of CDAD might still 
suggest an indirect relationship with meropenem or piperacillin tazobactam. 
The third limitation was that the present study used C. difficile toxin B test and the 
number of unformed or watery stool to diagnose CDAD. The toxin test was reported 
to be only 70 80% sensitive.
27 Other published diagnostic methods include positive 
stool  culture  for  C.  difficile,  positive  assay  for  toxin  A  in  a  stool  sample, 
characteristics  of  C.  difficile  infection  on  colonic  biopsy,  and  pseudomembranous 
colitis observed on lower gastrointestinal endoscopy.
27 In addition, certain diets and 
medications might have caused constipation and masked the number of loose stools 
per day, which is important for the diagnosis of CDAD. Therefore, the incidence of 
CDAD observed in the current study could be an underestimate. 
 
Conclusions 
 
Based  on the information in  the current  study,  there  was  not enough evidence to 
support  that  piperacillin tazobactam  had  a  lower  incidence  of  CDAD  than 
meropenem.  The  study  lacked  evidence  to  suggest  a  significant  difference  in  the 
incidence of in hospital mortality. The study also failed to show significant difference 
in incidence of CDAD between the two antibiotics in high risk patients. The results 
should not warrant the use of one antibiotic over another to prevent CDAD. Further 
research, involving larger sample size and prospective study design, is still needed to 
help selecting the safest antibiotic for patients. Knowing the prevalence of CDAD can International Journal of Collaborative Research on Internal Medicine & Public Health 
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help  health  institutions  in  establishing  a  protocol  in  choosing  between  the  two 
antibiotics. 
Using  the  current  incidence  rate  of  CDAD  in  the  meropenem  and  piperacillin 
tazobactam  groups  (3.57%  and  4.92%,  respectively),  researchers  can  perform  a 
prospective randomized controlled trial to confirm the results of the current study. A 
sample size calculation with dichotomous outcome variables, a two tailed alpha of 
5%, and a beta of 80% can be used.
22 A minimum of 3500 patients would be needed 
per group to detect an effect size difference of 1.35%. In addition, the new trial should 
be a multi centred study with a sensitive diagnostic test and exclusion of confounders 
described  above.  It  is  necessary  to  reduce  the  incidence  of  this  life threatening 
diarrhea, which is a huge financial burden for the healthcare system. 
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Figure 1. Flow diagram of patient selection. International Journal of Collaborative Research on Internal Medicine & Public Health 
 
 
 
 
 
    Vol. 4 No. 8 (2012) 
1576 
 
 
Table 1. Demographic Characteristics of Patients Treated with Meropenem and Piperacillin-Tazobactam
Number (%) of Patients
Meropenem Piperacillin-tazobactam p value
Characteristic (n = 168) (n = 122)
Males 80 (47.62) 75 (61.48) 0.0235
Age > 65 years 99 (58.93) 75 (61.48) 0.7162
Stayed > 28 days in health care settings 90 (53.57) 64 (52.46) 0.9053
Had concurrent high risk drugs within 2 months* 163 (97.02) 118 (96.72) 1.0000
Had Saccharomyces boulardii in 2 months prior 6 (3.57) 4 (3.28) 1.0000
Had po/iv metronidazole, or po vancomycin in 2 months prior 22 (13.10) 22 (18.03) 0.2515
*High risk drugs: antineoplastic agents, tacrolimus, histamine 2 receptor antagonists, proton pump inhibitors, 
   non steroidal anti inflammatory drugs, and systemic antibiotics (except vancomycin and metronidazole)
 
 
Table 2. Analysis of Clostridium difficile Associated Diarrhea Incidence and Mortality Rates
Number (%) of Patients
Meropenem Piperacillin-tazobactam p value Absolute difference [95% CI]
Outcome (n = 168) (n = 122)
Primary
Had CDAD 6 (3.57) 6 (4.92) 0.5676 1.35% [–3.30% to 6.00%]
Secondary
Died within 2 months in hospital 58 (34.52) 45 (36.89) 0.7102 2.36% [–8.80% to 13.52%]
Had CDAD or died within 2 months in hospital 63 (37.50) 49 (40.16) 0.7142 2.66% [–8.69% to 14.02%]
CDAD = Clostridium difficile associated diarrhea
CI = confidence interval
 
 
Table 3. Subgroup Analysis of Patients with Risk Factors for Clostridium difficile Associated Diarrhea
Number (%) of Patients
Subgroups Meropenem Piperacillin-tazobactam p value
n With CDAD n With CDAD
Males 80 2 (2.50%) 75 5 (6.67%) 0.2646
Age > 65 years 99 5 (5.05%) 75 5 (6.67%) 0.7472
Stayed > 28 days in health care settings 90 5 (5.56%) 64 4 (6.25%) 1.0000
Had concurrent high risk drugs within 2 months* 163 6 (3.68%) 118 6 (5.08%) 0.5667
Not on Saccharomyces boulardii in 2 months prior 162 5 (3.09%) 118 5 (4.24%) 0.7471
Not on po/iv metronidazole, or po vancomycin in 2 months prior 146 4 (2.74%) 100 6 (6.00%) 0.3242
*High risk drugs: antineoplastic agents, tacrolimus, histamine 2 receptor antagonists, proton pump inhibitors, 
     non steroidal anti inflammatory drugs, and systemtic antibiotics (except metronidazole and vancomycin)
CDAD = Clostridium difficile associated diarrhea
 
 